Abstract
ObjectiveTo compare the impact of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on cardiovascular outcomes in adults taking maximally tolerated statin therapy or who are statin intolerant.DesignNetwork meta-analysis.Data...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have